Cilostazol improves cognitive function in patients with mild cognitive impairment: A retrospective analysis

Psychogeriatrics

Volumn 13, Issue 3, 2013, Pages 164-169

  Taguchi, Akihiko ^a   Takata, Yu ^b   Ihara, Masafumi ^a   Kasahara, Yukiko ^a   Tsuji, Masahiro ^a   Nishino, Madoka ^b   Stern, David ^c   Okada, Masahiro ^b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b Department of Neurosurgery   (Japan)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Antiplatelet drug; Cerebral circulation; Cilostazol; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN; CILOSTAZOL; NEUROPROTECTIVE AGENT; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BRAIN CIRCULATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY;

AGED; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; TETRAZOLES;

EID: 84884727142     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/psyg.12021     Document Type: Article

References (10)

1. Taguchi A. Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16: 859-864.
2. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.
3. Shinohara Y, Katayama Y, Uchiyama S etal. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-968.
4. Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012; 43: 499-506.
5. Tanaka K, Gotoh F, Fukuuchi Y etal. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989; 20: 668-673.
6. Park SH, Kim JH, Bae SS etal. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation. Biochem Biophys Res Commun 2011; 408: 602-608.
7. Kamiyama K, Wada A, Sugihara M etal. Potential hippocampal region atrophy in diabetes mellitus type 2: a voxel-based morphometry VSRAD study. Jpn J Radiol 2010; 28: 266-272.
8. Stephan BC, Brayne C, McKeith IG, Bond J, Matthews FE. Mild cognitive impairment in the older population: who is missed and does it matter? Int J Geriatr Psychiatry 2008; 23: 863-871.
9. Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc 2007; 55: 1534-1540.
10. Arai H, Takahashi T. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 2009; 17: 353-354.